Supportive care is often misunderstood as an additional service offered alongside cancer treatment. In reality, it is one of the foundations that allows treatment to be delivered safely, consistently, and with the patient’s quality of life in mind.
A new commentary from leaders within the Multinational Association for Supportive Care in Cancer (MASCC) challenges the myths that continue to keep supportive care at the margins of oncology. The authors argue that preventing and managing toxicities, protecting physical and mental well-being, supporting caregivers, and reducing financial strain are not secondary concerns. They are essential parts of excellent cancer care.
Supportive care begins at diagnosis and continues through treatment, survivorship, and, when needed, end-of-life care. It includes the prevention and management of symptoms such as nausea, oral mucositis, neuropathy, fatigue, cachexia, infection risk, psychological distress, and long-term treatment complications.
Its purpose is clear: to help patients tolerate treatment, maintain their daily functioning, avoid unnecessary interruptions, and receive the full benefit of cancer therapy.
More Than Comfort: The Clinical Value of Supportive Care
One of the most persistent misconceptions is that supportive care is simply about comfort.
Comfort matters. But supportive care goes much further. It is an evidence-based, multidisciplinary approach that can influence treatment feasibility, functional status, adherence, and survival.
When side effects are prevented or managed early, patients are more likely to maintain dose intensity, avoid emergency admissions, recover between treatment cycles, and continue potentially life-saving therapy as planned.
Many supportive care interventions have become so embedded in cancer treatment that their importance is sometimes overlooked. Autologous hematopoietic stem-cell transplantation is one example. It allows patients to receive high-dose chemotherapy or total-body irradiation while restoring bone marrow function afterward. What was once considered a pioneering supportive intervention is now a standard component of treatment for diseases such as multiple myeloma and aggressive lymphoma.
Antiemetics offer another example. They were once viewed as adjunctive care but are now a routine and expected part of many treatment protocols.
These interventions illustrate a central point: supportive care does not sit outside cancer treatment. It makes cancer treatment possible.
Whose Responsibility Is Supportive Care?
Supportive care is sometimes assumed to belong to someone else: palliative care teams, nurses, psycho-oncology services, pharmacists, dietitians, or downstream referral services.
The commentary argues that this fragmented approach creates gaps in care.
Optimal supportive care requires shared ownership across the multidisciplinary cancer team. Oncologists, nurses, pharmacists, dietitians, dental professionals, psycho-oncology specialists, allied health teams, researchers, patients, and caregivers all have a role.
The goal is not to outsource supportive care. It is to embed it into routine oncology practice.
This matters because symptoms can escalate quickly when they are not recognized early. A patient experiencing neuropathy, for example, may face consequences that are not immediately apparent in a routine clinic visit. Mild neuropathy may be manageable for one person but career-threatening for someone whose work depends on fine motor skills.
Supportive care needs to reflect the individual patient’s priorities, lifestyle, treatment goals, and risks.
Supportive Care Does Not Start at the End of Life
Supportive care is often confused with palliative care. While the two areas overlap, they are not identical.
Palliative care has traditionally been associated with advanced or life-limiting disease, although it is increasingly integrated earlier in the cancer journey. Supportive care, however, is relevant across the entire continuum of care.
It begins at diagnosis. It continues during active treatment. It remains important during survivorship.
The distinction matters because many patients and clinicians still associate palliative care with stopping active treatment. This misunderstanding can delay referrals and prevent patients from receiving timely help.
Supportive care focuses on proactive intervention. It aims to prevent complications before they become severe, identify symptoms early, support treatment adherence, and protect quality of life throughout the cancer journey.
As the authors note, all palliative care is supportive, but not all supportive care is palliative.
Side Effects Are Common, but They Are Not Always Inevitable
Cancer treatment toxicities are often treated as unavoidable consequences of therapy. The authors challenge this belief.
Many side effects are predictable. Some are preventable. Others can be reduced in severity through early recognition and timely intervention.
Patient-reported outcomes and patient-reported experience measures can help clinicians identify symptoms that may otherwise go unnoticed. These tools allow patients to report problems such as pain, fatigue, nausea, emotional distress, sleep difficulties, neuropathy, or functional decline in real time.
When these concerns are detected early, care teams can intervene before symptoms become severe enough to lead to treatment delays, hospital admissions, dose reductions, or discontinuation.
The use of patient-reported outcomes can also help align treatment with what matters most to the individual. Not every symptom has the same impact on every patient. Supportive care becomes more effective when it is based on a patient’s daily life, work, responsibilities, and goals.
Precision Treatment Has Not Eliminated Toxicity
Modern oncology has moved toward more precise treatment approaches, including targeted therapies, immunotherapies, cellular therapies, antibody-drug conjugates, and advanced radiation techniques.
These treatments have changed the toxicity landscape. They have not removed it.
Targeted agents and immunotherapies can cause serious and sometimes unexpected adverse events. CAR-T cell therapy, for example, can be associated with cytokine release syndrome and significant neurological complications. Antibody-drug conjugates can also produce substantial toxicity despite their tumor-directed design.
The commentary highlights a meta-analysis of 169 trials involving antibody-drug conjugates, which reported an overall adverse-event rate of 91.2%. Grade 3 or higher events occurred in 46.1% of patients, while 13.2% discontinued treatment because of toxicity. Fatal adverse reactions were reported in 1.3% of cases.
As cancer therapies become more complex, supportive care must evolve alongside them. New toxicities require new recognition pathways, better risk assessment, stronger clinical coordination, and research into prevention and management.
Supportive Care Can Influence Survival
Supportive care is sometimes viewed as separate from survival outcomes. The evidence discussed in the commentary suggests otherwise.
Treatment-related toxicities can be fatal. They can also weaken treatment adherence, lead to dose reductions, delay therapy, and prevent patients from completing curative-intent treatment.
In some settings, treatment-related mortality can exceed cancer-related mortality. The commentary cites data from pediatric hematologic malignancies in which treatment-related deaths, largely driven by infections, were more common than disease-related deaths.
The effects of poorly controlled symptoms can also extend beyond physical health. Severe pain, psychological distress, dysphagia, disfigurement, and loss of function can deeply affect mental well-being and may contribute to serious outcomes, including suicide risk.
Early supportive and palliative care has been associated with better quality of life and longer survival in patients with metastatic non-small cell lung cancer and advanced cancer.
Supportive care does not distract from cancer treatment. It helps patients remain well enough to benefit from it.
A Scientific Field That Deserves Greater Investment
Supportive care is not simply a service-based discipline. It is a scientific field that includes epidemiology, biomarker research, pharmacogenomics, microbiome science, implementation research, health economics, clinical trials, and precision medicine.
Researchers are increasingly identifying biological and clinical factors that can predict toxicity risk. Pharmacogenomic testing, including DPYD genotyping, can help identify patients who may be at higher risk of severe treatment-related toxicity and guide safer dose adjustments.
The gut microbiome is also emerging as an important area of investigation. Changes in microbial composition have been linked to gastrointestinal side effects, bloodstream infections, graft-versus-host disease, and immune-mediated colitis.
Despite its scientific depth and clinical relevance, supportive care research remains underfunded compared with cancer biology and drug development.
The authors call for stronger investment across the full research pathway, from understanding the mechanisms behind symptoms to developing, testing, and implementing interventions that improve patient outcomes.
Better Supportive Care Can Also Reduce Costs
The belief that supportive care is too expensive is another barrier to implementation.
The authors argue that reactive care is often far more costly than prevention. Severe toxicities can lead to emergency visits, prolonged hospital stays, intensive care admissions, infection management, nutritional support, opioid use, and treatment delays.
Oral mucositis is one example. Severe mucositis can add several inpatient days for patients receiving chemoradiotherapy for head and neck cancer or undergoing stem-cell transplantation. The financial impact can be substantial, with additional costs ranging from thousands to tens of thousands of dollars per patient.
Preventive interventions can reduce this burden. Oral cryotherapy, for example, is relatively low-cost and has been associated with reduced mucositis, opioid use, length of stay, and nutritional requirements.
The commentary also points to the CHALLENGE trial, presented at the 2025 ASCO Annual Meeting. In nearly 900 patients with high-risk stage II and III colon cancer, a structured personalized exercise programme reduced the risk of recurrence or new cancers by 28% and lowered the risk of death by 37%.
Supportive care can improve sustainability for health systems while reducing the financial burden carried by patients and families.
Quality of Life Is Not a Secondary Outcome
Patients do not only care about living longer. They also care about how they live.
In a study of 743 patients with advanced cancer, 55% valued quality of life and length of life equally. Another 27% prioritized quality of life, while only 18% prioritized survival alone.
Symptoms can affect mobility, independence, work, relationships, finances, identity, and emotional well-being. For many patients, these outcomes are central to their treatment decisions.
Supportive care gives patients a stronger voice in the care process. It creates a structure for identifying what is most difficult, what is most important, and what needs to change.
Success in oncology should not be measured only by tumor response or months gained. Quality of life, function, tolerability, and the ability to continue meaningful daily activities also matter.
Supportive Care Must Include Caregivers
Cancer affects more than the person receiving treatment.
Family members and informal caregivers often experience substantial emotional, physical, and financial strain. They may face anxiety, depression, fatigue, work disruption, sleep problems, and the demands of managing symptoms and appointments at home.
Caregiver well-being directly affects the support patients receive.
Supportive care should therefore include education, psychosocial support, practical assistance, respite services, and resources for those caring for a person with cancer.
Recognizing caregivers as part of the cancer care ecosystem strengthens both patient outcomes and family well-being.
Making Supportive Care a Core Part of Oncology
The authors call for a shift in how supportive care is understood, funded, measured, and delivered.
Supportive care should be embedded in routine cancer pathways rather than positioned as a peripheral service. Oncology training should include supportive care competencies. Clinical trials should include supportive care endpoints. Patient-reported outcomes should be used more consistently in clinical practice.
Implementation must also reflect the realities of different health systems. In low- and middle-income settings, this may involve high-value, low-cost interventions, task-sharing models, digital symptom monitoring, stronger primary-care integration, and expanded roles for nurses, pharmacists, community health workers, and trained nonspecialists.
The future of cancer care will depend not only on the next treatment breakthrough. It will also depend on whether patients can safely receive, tolerate, and benefit from the treatments already available.
Supportive care is not an optional addition to oncology. It is what allows excellent cancer care to reach the person behind the diagnosis.
Written by Nare Hovhannisyan, MD
Explore more oncology news and features on OncoDaily